EP4709753A1 - Inhibiteurs de slc4a4/nbce1 - Google Patents

Inhibiteurs de slc4a4/nbce1

Info

Publication number
EP4709753A1
EP4709753A1 EP24724494.0A EP24724494A EP4709753A1 EP 4709753 A1 EP4709753 A1 EP 4709753A1 EP 24724494 A EP24724494 A EP 24724494A EP 4709753 A1 EP4709753 A1 EP 4709753A1
Authority
EP
European Patent Office
Prior art keywords
nbcel
slc4a4
inhibiting
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24724494.0A
Other languages
German (de)
English (en)
Inventor
Massimiliano Mazzone
Marie-Pauline ORBAN
Janine BRUNNER
Stephan Schenk
Bruno Dombrecht
Tobias LANGENBERG
Michele CURCIO
Gholamreza Hassanzadeh Ghassabeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB, Vrije Universiteit Brussel VUB filed Critical Katholieke Universiteit Leuven
Publication of EP4709753A1 publication Critical patent/EP4709753A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgation concerne des composés inhibant sélectivement l'élément 4 de la famille 4 des porteurs de soluté/le cotransporteur 1 de bicarbonate de sodium électrogène (SLC4A4/NBCe1). Plus particulièrement, lesdits composés sont des anticorps à domaine unique inhibant SLC4A4/NBCe1, des composés comprenant au moins un polypeptide CDR d'un anticorps à domaine unique inhibant SLC4A4/NBCe1, et des composés comprenant un anticorps à domaine unique inhibant SLC4A4/NBCe1. Des utilisations des composés inhibant SLC4A4/NBCe1 sont également divulguées.
EP24724494.0A 2023-05-11 2024-05-06 Inhibiteurs de slc4a4/nbce1 Pending EP4709753A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23172907 2023-05-11
PCT/EP2024/062462 WO2024231348A1 (fr) 2023-05-11 2024-05-06 Inhibiteurs de slc4a4/nbce1

Publications (1)

Publication Number Publication Date
EP4709753A1 true EP4709753A1 (fr) 2026-03-18

Family

ID=86331833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24724494.0A Pending EP4709753A1 (fr) 2023-05-11 2024-05-06 Inhibiteurs de slc4a4/nbce1

Country Status (4)

Country Link
EP (1) EP4709753A1 (fr)
CN (1) CN121511260A (fr)
IL (1) IL324501A (fr)
WO (1) WO2024231348A1 (fr)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
CA2241433A1 (fr) 1997-08-19 1999-02-19 Smithkline Beecham Laboratoires Pharmaceutiques Nouveaux composes
WO1999037681A2 (fr) 1998-01-26 1999-07-29 Unilever Plc Procede servant a preparer des fragments d'anticorps
US6723522B1 (en) * 1998-12-21 2004-04-20 Takeda Chemical Industries, Ltd. Sodium bicarbonate cotransporter protein
WO2000040968A1 (fr) 1999-01-05 2000-07-13 Unilever Plc Fixation de fragments d'anticorps a des supports solides
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1242460B1 (fr) 1999-11-29 2006-10-18 Unilever Plc Immobilisation de proteines a l'aide d'un segment polypeptidique
WO2001044301A1 (fr) 1999-11-29 2001-06-21 Unilever Plc Immobilisation de molecules de liaison d'antigene a domaine unique
EP1134231B1 (fr) 2000-03-14 2009-04-15 Unilever N.V. Domaines variables de la chaine lourde d'anticorps contre des lipases humaines alimentaires et leurs utilisations
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (fr) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Nouveaux immunoconjugues utiles pour le traitement de tumeurs
EP2284192A3 (fr) 2002-11-08 2011-07-20 Ablynx N.V. Anticorps de Camelidae pour administration sublinguale
EP1558647B1 (fr) 2002-11-08 2015-06-10 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (fr) 2003-08-12 2007-02-28 William M Yarbrough Traitement de l'acne simple et procede d'utilisation
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
CA2595682A1 (fr) 2005-01-31 2006-08-03 Ablynx N.V. Procede de generation de sequences a domaine variable d'anticorps a chaine lourde
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
EP3466972B1 (fr) 2011-06-23 2026-03-04 Ablynx NV Protéines de liaison de l'albumine sérique
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
CA3070253A1 (fr) 2017-07-19 2019-01-24 Vib Vzw Agents de liaison a la l'albumine serique
EP4294407A1 (fr) 2021-02-17 2023-12-27 Vib Vzw Inhibition de slc4a4 dans le traitement du cancer
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders

Also Published As

Publication number Publication date
WO2024231348A1 (fr) 2024-11-14
CN121511260A (zh) 2026-02-10
IL324501A (en) 2026-01-01

Similar Documents

Publication Publication Date Title
EP3818086B1 (fr) Traitement et prévention du cancer à l'aide de molécules de liaison à l'antigène her3
JP7314356B2 (ja) 改変ｊ鎖を有する結合分子
US11780933B2 (en) HER3 antigen-binding molecules
CN112703205B (zh) 抗间皮素抗体
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
KR20230146578A (ko) Bcma, gprc5d, 및 cd3을 표적화하는 삼중특이적 항체
KR102875986B1 (ko) Il27 수용체 결합과 관련된 조성물 및 방법
CN110835375B (zh) 一种抗pd-1/egfr双特异性抗体及其用途
KR20200003845A (ko) 이중특이성 재조합단백질 및 이의 응용
CN112442122B (zh) 阻断型pd-1纳米抗体及其编码序列和用途
TW201607959A (zh) Ｃｄｈ１９及ｃｄ３抗體構築體
US20240209106A1 (en) Anti-cd137 antibodies and methods of use
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
CN121358777A (zh) 抗mageb2的抗原结合蛋白
WO2024231348A1 (fr) Inhibiteurs de slc4a4/nbce1
KR20220155588A (ko) Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법
EP4613774A1 (fr) Anticorps à domaine unique ciblant ror1 humain
US20260132219A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
WO2025218621A1 (fr) Protéine de liaison à l'antigène ciblant muc1
WO2024173565A2 (fr) Anticorps synthétiques humains ciblant des mutations du récepteur 2 du facteur de croissance épidermique humain (her2)
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40026637A (en) Her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR